# US 2005/0090495 A1 · Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0090495 A1
- Document ID: US20050090495A1
- Status: Published application
- Kind: A1
- Application number: 10/671,205
- Filed: 2003-09-25
- Published: 2005-04-28
- Earliest claimed: 1997-07-10
- Inventors: Jean Lacrampe; Eddy Freyne; Marc Venet; Gustaaf Boeckx
- Web page: https://patentgrep.com/patent/US20050090495A1

## CPC

- C07D 401/10: linked by a carbon chain containing aromatic rings
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/10: linked by a carbon chain containing aromatic rings
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is concerned with the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, p and q are 0, 1, 2, 3 or 4 and q is also 5; X is O, S, NR3 or a direct bond; R1 is hydrogen, hydroxy, halo, optionally substituted amino, optionally substituted C1-6alkyl, C1-6alkyloxy, C3-7cycloalkyl or aryl; R2 is aryl, Het1, C3-7cycloalkyl, optionally substituted C1-6alkyl; and if X is O, S or NR3, then R2 may also be a carbonyl or thiocarbonyl linked substituent; R3 is hydrogen or C1-4allyl; R4 and R5 independently are optionally substituted C1-6alkyl, halo, hydroxy, mercapto, C1-6alkyloxy, C1-6alkylthio, C1-6alkylcarbonyloxy, aryl, cyano, nitro, Het3, R6 or NR7R8; R6 is substituted sulfonyl or sulfinyl; R7 and R8 are hydrogen, optionally substituted C1-4alkyl, aryl, a carbonyl or thiocarbonyl linked substituent, C3-7cycloalkyl, Het3 and R6; R9 and R10 are each independently selected from hydrogen, optionally substituted C1-4alkyl, phenyl, a carbonyl or thiocarbonyl linked substituent, C3-7cycloalkyl, Het3 and R6; R11 is hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C1-4alkyloxy, carboxyl, C1-4alkyloxycarbonyl, trihaloC1-4alkylsulfonyloxy, R6, NR7R8, C(═O)NR7R3, aryl, aryloxy, arylcarbonyl, C3-7cycloalkyl, C3-7cycloalkyloxy, phthalimide-2-yl, Het3 and C(═O)Het3; R12 and R13 are each independently selected from hydrogen, optionally substituted C1-4alkyl, phenyl, a carbonyl or thiocarbonyl linked substituent, C3-7cycloalkyl and R6; aryl is optionally substituted phenyl; Het1, Het2 and Het3 are optionally substituted heterocycles; to processes for their preparation and compositions comprising them. It further relates to their use as a medicine.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A method of marking or identifying a receptor comprising the steps of:
a) radiolabelling a compound of formula (I)
a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein:
p represents an integer being 0, 1, or 2;
q represents an integer being 0, 1, or 2;
X represents O, S, NR3 or a direct bond;
R1 represents hydrogen, hydroxy, halo, amino, C1-6alkyl, C1-6alkyloxy or mono- or di(C1-4alkyl)aminoC1-4alkylamino; in particular, hydrogen, methyl and hydroxy;
R2 represents oxadiazolyl, thiazolyl, pyrimidinyl or pyridinyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het2, R11 and C1-4alkyl optionally substituted with Het2 or R11;
each R4 independently represents C1-6alkyl, halo, polyhaloC1-6alkyl or C1-6alkyloxy;
each R5 independently represents C1-6alkyl, halo or C1-6alkyloxy;
each R6 independently represents C1-6alkylsulfonyl, aminosulfonyl or phenylC1-4alkylsulfonyl;
each R7 and each R8 are independently selected from hydrogen, C1-4alkyl, hydroxyC1-4alkyl, dihydroxyC1-4alkyl, aryl, arylC1-4alkyl, C1-4alkyloxyC1-4alkyl, mono- or di(C1-4alkyl)aminoC1-4alkyl, arylaminocarbonyl, arylaminothiocarbonyl, C3-7cycloalkyl, pyridinylC1-4alkyl, Het3 and R6;
R9 and R10 are each independently selected from hydrogen, C1-4alkyl, C1-4alkylcarbonyloxyC1-4alkylcarbonyl, hydroxyC1-4alkylcarbonyl, C1-4alkyloxycarbonylcarbonyl, Het3aminothiocarbonyl and R6;
each R11 independently being selected from hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C1-4alkyloxy, carboxyl, C1-4alkyloxycarbonyl, trihaloC1-4alkylsulfonyloxy, R6, NR7R8, C(═O)NR7R8, aryl, aryloxy, arylcarbonyl, C3-7cycloalkyl, C3-7cycloalkyloxy, phthalimide-2-yl, Het3 and C(═O)Het3;
R12 and R13 are each independently selected from hydrogen and C1-4alkyl; aryl represents phenyl optionally substituted with one, two or three substituents each independently selected from nitro, azido, halo, hydroxy, C1-4alkyl, C1-4alkyloxy, polyhaloC1-4alkyl, NR9R10, R6, phenyl, Het3 and C1-4alkyl substituted with NR9R10;
Het1 represents a heterocycle selected from a heterocycle selected from imidazolyl, triazolyl, furanyl, oxazolyl, thiazolyl, thiazolinyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, piperidinyl, piperazinyl, triazinyl, benzothiazolyl, benzoxazolyl, purinyl, 1H-pyrazolo-[3,4-d]pyrimidinyl, benzimidazolyl, thiazolopyridinyl, oxazolopyridinyl, imidazo-[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het2, R11 and C1-4alkyl optionally substituted with Het2 or R11;
Het2 represents furanyl, thienyl or pyridinyl; wherein said monocyclic heterocycles each independently may optionally be substituted with C1-4alkyl;
Het3 represents pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; wherein said monocyclic heterocycles each independently may optionally be substituted with, where possible, one, two or three substituents each independently selected from C1-4alkyl, C1-4alkyloxy, C1-4alkyloxycarbonyl, C1-4alkylcarbonyl, phenylC1-4alkyl, piperidinyl, NR12R13 and C1-4alkyl substituted with NR12R13;
b) administering said radiolabelled compound to biological material; and
c) detecting the emissions from the radiolabelled compound.

### Claim 14 (depends on 13)

The method of claim 13 wherein the 6-azauracil moiety of said compound according to claim 13 is in the para position relative to the central carbon atom.

### Claim 15 (depends on 13)

The method of claim 13 wherein the 6-azauracil moiety of said compound according to claim 13 is in the para position relative to the central carbon atom; q is 1 or 2 and one R4 substituent is in the 4 position; and p is 1 or 2 and the one or two R5 substituents are in the ortho position relative to the central carbon atom.

### Claim 16 (depends on 13)

The method of claim 13 wherein one or more atoms in the compound are replaced by radioactive isotopes.

### Claim 17 (depends on 13)

The method of claim 13 wherein the compound comprises at least one halo which is a radioactive isotope of iodine, bromine, or fluorine.

### Claim 18 (depends on 13)

The method of claim 13 wherein the compound comprises at least one 11C-atom or tritium atom.

### Claim 19 (depends on 13)

The method of claim 13 wherein R3 and/or R4 are a radioactive halogen atom.

### Claim 20

A method of imaging an organ comprising the steps of:
a) radiolabelling a compound of formula (I)
a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein:
p represents an integer being 0, 1, or 2;
q represents an integer being 0, 1, or 2;
X represents O, S, NR3 or a direct bond;
R1 represents hydrogen, hydroxy, halo, amino, C1-6alkyl, C1-6alkyloxy or mono- or di(C1-4alkyl)aminoC1-4alkylamino; in particular, hydrogen, methyl and hydroxy;
R2 represents oxadiazolyl, thiazolyl, pyrimidinyl or pyridinyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het2, R11 and C1-4alkyl optionally substituted with Het2 or R11;
each R4 independently represents C1-6alkyl, halo, polyhaloC1-6alkyl or C1-6alkyloxy;
each R5 independently represents C1-6alkyl, halo or C1-6alkyloxy;
each R6 independently represents C1-6alkylsulfonyl, aminosulfonyl or phenylC1-4alkylsulfonyl;
each R7 and each R8 are independently selected from hydrogen, C1-4alkyl, hydroxyC1-4alkyl, dihydroxyC1-4alkyl, aryl, arylC1-4alkyl, C1-4alkyloxyC1-4alkyl, mono- or di(C1-4alkyl)aminoC1-4alkyl, arylaminocarbonyl, arylaminothiocarbonyl, C3-7cycloalkyl, pyridinylC1-4alkyl, Het3 and R6;
R9 and R10 are each independently selected from hydrogen, C1-4alkyl, C1-4alkylcarbonyloxyC1-4alkylcarbonyl, hydroxyC1-4alkylcarbonyl, C1-4alkyloxycarbonylcarbonyl, Het3aminothiocarbonyl and R6;
each R11 independently being selected from hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C1-4alkyloxy, carboxyl, C1-4alkyloxycarbonyl, trihaloC1-4alkylsulfonyloxy, R6, NR7R8, C(═O)NR7R8, aryl, aryloxy, arylcarbonyl, C3-7cycloalkyl, C3-7cycloalkyloxy, phthalimide-2-yl, Het3 and C(═O)Het3;
R12 and R13 are each independently selected from hydrogen and C1-4alkyl; aryl represents phenyl optionally substituted with one, two or three substituents each independently selected from nitro, azido, halo, hydroxy, C1-4alkyl, C1-4alkyloxy, polyhaloC1-4alkyl, NR9R10, R6, phenyl, Het3 and C1-4alkyl substituted with NR9R10;
Het1 represents a heterocycle selected from a heterocycle selected from imidazolyl, triazolyl, furanyl, oxazolyl, thiazolyl, thiazolinyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, piperidinyl, piperazinyl, triazinyl, benzothiazolyl, benzoxazolyl, purinyl, 1H-pyrazolo-[3,4-d]pyrimidinyl, benzimidazolyl, thiazolopyridinyl, oxazolopyridinyl, imidazo-[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het2, R11 and C1-4alkyl optionally substituted with Het2 or R11;
Het2 represents furanyl, thienyl or pyridinyl; wherein said monocyclic heterocycles each independently may optionally be substituted with C1-4alkyl;
Het3 represents pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; wherein said monocyclic heterocycles each independently may optionally be substituted with, where possible, one, two or three substituents each independently selected from C1-4alkyl, C1-4alkyloxy, C1-4alkyloxycarbonyl, C1-4alkylcarbonyl, phenylC1-4alkyl, piperidinyl, NR12R13 and C1-4alkyl substituted with NR12R13;
b) administering a sufficient amount of said radiolabelled compound in an appropriate composition to an animal; and
c) detecting the location of said radiolabelled compound.

### Claim 21 (depends on 20)

The method of claim 20 wherein the 6-azauracil moiety of said compound according to claim 20 is in the para position relative to the central carbon atom.

### Claim 22 (depends on 20)

The method of claim 20 wherein the 6-azauracil moiety of said compound according to claim 20 is in the para position relative to the central carbon atom; q is 1 or 2 and one R4 substituent is in the 4 position; and p is 1 or 2 and the one or two R5 substituents are in the ortho position relative to the central carbon atom.

### Claim 23 (depends on 20)

The method of claim 20 wherein one or more atoms in the compound are replaced by radioactive isotopes.

### Claim 24 (depends on 20)

The method of claim 20 wherein the compound comprises at least one halo which is a radioactive isotope of iodine, bromine, or fluorine.

### Claim 25 (depends on 20)

The method of claim 20 wherein the compound comprises at least one 11C-atom or tritium atom.

### Claim 26 (depends on 20)

The method of claim 20 wherein R3 and/or R4 are a radioactive halogen atom.

### Claim 27 (depends on 20)

The method of claim 20 wherein the location of said radiolabelled compounds is detected using imaging techniques.

### Claim 28 (depends on 27)

The method of claim 27 wherein said imaging techniques comprises positron emission tomography.

### Claim 29 (depends on 27)

The method of claim 27 wherein said imaging techniques comprises single photon emission computerized tomography.

### Claim 30 (depends on 13)

The method of claim 13 wherein said biological material comprises an animal.

### Claim 31 (depends on 13)

The method of claim 13, wherein said biological material comprises a human being.

### Claim 32 (depends on 13)

The method of claim 13, wherein said biological material comprises a tissue sample.

### Claim 33 (depends on 13)

The method of claim 13 wherein the emissions of said radiolabelled compounds is detected using imaging techniques.

### Claim 34 (depends on 33)

The method of claim 33 wherein said imaging techniques comprises positron emission tomography.

### Claim 35 (depends on 33)

The method of claim 33 wherein said imaging techniques comprises single photon emission computerized tomography.

### Claim 36

A method of evaluating receptor binding ability of a test compound, comprising the steps of:
a) radiolabelling a compound of formula (I)
a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein:
p represents an integer being 0, 1, or 2;
q represents an integer being 0, 1, or 2;
X represents O, S, NR3 or a direct bond;
R1 represents hydrogen, hydroxy, halo, amino, C1-6alkyl, C1-6alkyloxy or mono- or di(C1-4alkyl)aminoC1-4alkylamino; in particular, hydrogen, methyl and hydroxy;
R2 represents oxadiazolyl, thiazolyl, pyrimidinyl or pyridinyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het2, R11 and C1-4alkyl optionally substituted with Het2 or R11;
each R4 independently represents C1-6alkyl, halo, polyhaloC1-6alkyl or C1-6alkyloxy;
each R5 independently represents C1-6alkyl, halo or C1-6alkyloxy;
each R6 independently represents C1-6alkylsulfonyl, aminosulfonyl or phenylC1-4alkylsulfonyl;
each R7 and each R8 are independently selected from hydrogen, C1-4alkyl, hydroxyC1-4alkyl, dihydroxyC1-4alkyl, aryl, arylC1-4alkyl, C1-4alkyloxyC1-4alkyl, mono- or di(C1-4alkyl)aminoC1-4alkyl, arylaminocarbonyl, arylaminothiocarbonyl, C3-7cycloalkyl, pyridinylC1-4alkyl, Het3 and R6;
R9 and R10 are each independently selected from hydrogen, C1-4alkyl, C1-4alkylcarbonyloxyC1-4alkylcarbonyl, hydroxyC1-4alkylcarbonyl, C1-4alkyloxycarbonylcarbonyl, Het3aminothiocarbonyl and R6;
each R11 independently being selected from hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C1-4alkyloxy, carboxyl, C1-4alkyloxycarbonyl, trihaloC1-4alkylsulfonyloxy, R6, NR7R8, C(═O)NR7R8, aryl, aryloxy, arylcarbonyl, C3-7cycloalkyl, C3-7cycloalkyloxy, phthalimide-2-yl, Het3 and C(═O)Het3;
R12 and R13 are each independently selected from hydrogen and C1-4alkyl; aryl represents phenyl optionally substituted with one, two or three substituents each independently selected from nitro, azido, halo, hydroxy, C1-4alkyl, C1-4alkyloxy, polyhaloC1-4alkyl, NR9R10, R6, phenyl, Het3 and C1-4alkyl substituted with NR9R10;
Het1 represents a heterocycle selected from a heterocycle selected from imidazolyl, triazolyl, furanyl, oxazolyl, thiazolyl, thiazolinyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, piperidinyl, piperazinyl, triazinyl, benzothiazolyl, benzoxazolyl, purinyl, 1H-pyrazolo-[3,4-d]pyrimidinyl, benzimidazolyl, thiazolopyridinyl, oxazolopyridinyl, imidazo-[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het2, R11 and C1-4alkyl optionally substituted with Het2 or R11;
Het2 represents furanyl, thienyl or pyridinyl; wherein said monocyclic heterocycles each independently may optionally be substituted with C1-4alkyl;
Het3 represents pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; wherein said monocyclic heterocycles each independently may optionally be substituted with, where possible, one, two or three substituents each independently selected from C1-4alkyl, C1-4alkyloxy, C1-4alkyloxycarbonyl, C1-4alkylcarbonyl, phenylC1-4alkyl, piperidinyl, NR12R13 and C1-4alkyl substituted with NR12R13;
b) administering said radiolabelled compound to biological material; and
c) detecting displacement of said compound of formula (I) by said test compound.

### Claim 37 (depends on 36)

The method of claim 36 wherein the 6-azauracil moiety of said compound according to claim 36 is in the para position relative to the central carbon atom.

### Claim 38 (depends on 20, 36)

The method of claim 36 wherein the 6-azauracil moiety of said compound according to claim 20 is in the para position relative to the central carbon atom; q is 1 or 2 and one R4 substituent is in the 4 position; and p is 1 or 2 and the one or two R5 substituents are in the ortho position relative to the central carbon atom.

### Claim 39 (depends on 36)

The method of claim 36 wherein one or more atoms in the compound are replaced by radioactive isotopes.

### Claim 40 (depends on 36)

The method of claim 36 wherein the compound comprises at least one halo which is a radioactive isotope of iodine, bromine, or fluorine.

### Claim 41 (depends on 36)

The method of claim 36 wherein the compound comprises at least one 11C-atom or tritium atom.

### Claim 42 (depends on 36)

The method of claim 36, wherein R3 and/or R4 are a radioactive halogen atom.
